...
首页> 外文期刊>Vaccine >Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts
【24h】

Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts

机译:通过在活体动物宿主中传代来增强生物工程单核细胞增生李斯特菌的免疫原性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Bioengineered Listeria monocytogenes can be used as a recombinant bacterial vaccine vector for the induction of strong cell-mediated immunity to passenger antigens. Listeria loses virulence after undergoing bioengineering techniques, thus decreasing its efficacy as a vaccine vector. We addressed this problem by examining the virulence, and the ability to induce CD8(+) T-cells, of Listeria monocytogenes vaccine strains before and after passaging through mice. We found that two in vivo passages are required to restore the induction of cell-mediated immunity to passenger antigens and maximum virulence to these strains. In addition, we found that after each passage, harvested bacteria must be cloned and checked for expression of the bioengineered gene to counter selection in favor of antigen loss mutants.
机译:生物工程化的单核细胞增生李斯特菌可用作重组细菌疫苗载体,用于诱导对乘客抗原的强细胞介导免疫。李斯特菌经过生物工程技术后丧失了毒性,因此降低了其作为疫苗载体的功效。我们通过检查在通过小鼠之前和之后的李斯特菌单核细胞增生性李斯特菌疫苗菌株的毒力和诱导CD8(+)T细胞的能力,解决了这个问题。我们发现需要两个体内传代来恢复诱导的细胞介导的对客运抗原的免疫力和对这些菌株的最大毒力。此外,我们发现每次传代后,必须克隆收获的细菌,并检查生物工程基因的表达以对抗选择有利于抗原损失突变体的生物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号